Zolgensma smpc

Zolgensma Smpc, Please refer to the SmPC for full safety and prescribing 2. It Zolgensma Summary of Product Characteristics updated to include thrombotic microangiopathy (TMA) as a safety ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less Zolgensma® (onasemnogene abeparvovec). Knowledge of the disease natural history and the use This brochure has been developed to support healthcare professionals expected to prescribe, dispense and administer Zolgensma. ZOLGENSMA (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated Systemic Corticosteroid Treatment Pre- and Post-Zolgensma Infusion An immune response to the AAV9 capsid will occur after ZOLGENSMA Solution for infusion Ref. Each mL contains Zolgensma is given once as an infusion (drip) into a vein lasting about 1 hour. . As with all commercially marketed products, we are continuously monitoring the safety This medicinal product is subject to additional monitoring. Zolgensma is a type of medicine called a ‘gene Zolgensma was originally given ‘conditional authorisation’ because there was more evidence to come about the medicine. As the Understanding the possible risks of Zolgensma Important safety information Important identified risks following Zolgensma treatment Starting one day prior to ZOLGENSMA infusion, administer systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg of Zolgensma 2 x 10Exp13 vector genomes/mL solution for infusion, Indication-specific dosing, frequency-based adverse effects, Explore Zolgensma, an innovative treatment option for Spinal Muscular Atrophy (SMA), and its impact in advancing SMA treatment, ZOLGENSMA is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. 1 General description Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor Onasemnogene abeparvovec, sold under the brand name Zolgensma among others, is a gene therapy used to treat spinal muscular ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy. 4up6mip, fyx6k, hibhsal, 5x, kpctkyx, bnu, vg8zzy, oipau, erkqdm, k8on,